{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:21:51Z","timestamp":1767666111282},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,8,15]]},"DOI":"10.2169\/internalmedicine.6755-20","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:06:39Z","timestamp":1614549999000},"page":"2607-2612","source":"Crossref","is-referenced-by-count":3,"title":["Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas"],"prefix":"10.2169","volume":"60","author":[{"given":"Haruo","family":"Miwa","sequence":"first","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sugimori","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Funaoka","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sugimori","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Tozuka","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Numata","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.pan.2016.09.011","volume":"16","author":"LN Nilsson","year":"2016","unstructured":"1. Nilsson LN, Keane MG, Shamali A, et al. Nature and management of pancreatic mucinous cystic neoplasm (MCN): a systematic review of the literature. Pancreatology 16: 1028-1036, 2016.","journal-title":"Pancreatology","ISSN":"http:\/\/id.crossref.org\/issn\/1424-3903","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Postlewait LM, Ethun CG, McInnis MR, et al. Association of preoperative risk factors with malignancy in pancreatic mucinous cystic neoplasms: a multicenter study. JAMA Surg 152: 19-25, 2017.","DOI":"10.1001\/jamasurg.2016.3598"},{"key":"3","unstructured":"3. Shimada K, Iwase K, Aono T, et al. A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine. Gan To Kagaku Ryoho 36: 995-998, 2009."},{"key":"4","unstructured":"4. Bj\u00f6rk Werner J, Sturesson C, Dawiskiba S, Andersson R. Mucinous cystadenocarcinoma of the pancreas - outcome following different modes of treatment. Ann Gastroenterol 24: 213-217, 2011."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.","DOI":"10.1056\/NEJMoa1011923"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013.","DOI":"10.1056\/NEJMoa1304369"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Brunetti O, Aprile G, Marchetti P, et al. Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis. Pancreas 47: 759-771, 2018.","DOI":"10.1097\/MPA.0000000000001063"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 230: 152-161, 1999.","DOI":"10.1097\/00000658-199908000-00004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 8: 213-219, 2010.","DOI":"10.1016\/j.cgh.2009.10.001"},{"key":"10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pan.2012.04.004","volume":"12","author":"M Tanaka","year":"2012","unstructured":"10. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12: 183-197, 2012.","journal-title":"Pancreatology","ISSN":"http:\/\/id.crossref.org\/issn\/1424-3903","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Goh BK, Tan YM, Chung YF, et al. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg 30: 2236-2245, 2006.","DOI":"10.1007\/s00268-006-0126-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Scholten L, van Huijgevoort NCM, van Hooft JE, Besselink MG, Del Chiaro M. Pancreatic cystic neoplasms: different types, different management, new guidelines. Visc Med 34: 173-177, 2018.","DOI":"10.1159\/000489641"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Garces-Descovich A, Beker K, Castillo-Angeles M, et al. Mucinous cystic neoplasms of the pancreas: high-resolution cross-sectional imaging features with clinico-pathologic correlation. Abdom Radiol (NY) 43: 1413-1422, 2018.","DOI":"10.1007\/s00261-017-1326-x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. European Study Group on Cystic Tumours of the P. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67: 789-804, 2018.","DOI":"10.1136\/gutjnl-2018-316027"},{"key":"15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00006676-200404000-00005","volume":"28","author":"Y Suzuki","year":"2004","unstructured":"15. Suzuki Y, Atomi Y, Sugiyama M, et al. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28: 241-246, 2004.","journal-title":"Pancreas","ISSN":"http:\/\/id.crossref.org\/issn\/0885-3177","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Doulamis IP, Mylonas KS, Kalfountzos CE, Mou D, Haj-Ibrahim H, Nasioudis D. Pancreatic mucinous cystadenocarcinoma: epidemiology and outcomes. Int J Surg 35: 76-82, 2016.","DOI":"10.1016\/j.ijsu.2016.09.017"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ueno H, Ikeda M, Ueno M, et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77: 595-603, 2016.","DOI":"10.1007\/s00280-016-2972-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Frese KK, Neesse A, Cook N, et al. Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2: 260-269, 2012.","DOI":"10.1158\/2159-8290.CD-11-0242"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Endo I, Ichikawa Y. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (Baltimore) 96: e6769, 2017.","DOI":"10.1097\/MD.0000000000006769"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim JH, Lee SC, Oh SY, et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Cancer Commun (London) 38: 32, 2018.","DOI":"10.1186\/s40880-018-0304-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chung MJ, Kang H, Kim HG, et al. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 10: 505-515, 2018.","DOI":"10.4251\/wjgo.v10.i12.505"},{"key":"22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-020-06945-8","volume":"20","author":"M Sawada","year":"2020","unstructured":"22. Sawada M, Kasuga A, Mie T, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 20: 449, 2020.","journal-title":"BMC Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6755-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T03:44:19Z","timestamp":1629517459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/16\/60_6755-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6755-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,15]]},"article-number":"6755-20"}}